BiotechTube

Troriluzole + Placebo + Troriluzole

Phase 2/3Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Spinocerebellar Ataxias

Conditions

Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1, Spinocerebellar Ataxia Genotype Type 2, Spinocerebellar Ataxia Genotype Type 3, Spinocerebellar Ataxia Genotype Type 6, Spinocerebellar Ataxia Genotype Type 7, Spinocerebellar Ataxia Genotype Type 8, Spinocerebellar Ataxia Genotype Type 10

Trial Timeline

Dec 15, 2016 → Sep 20, 2024

NCT ID
NCT02960893

About Troriluzole + Placebo + Troriluzole

Troriluzole + Placebo + Troriluzole is a phase 2/3 stage product being developed by Biohaven for Spinocerebellar Ataxias. The current trial status is completed. This product is registered under clinical trial identifier NCT02960893. Target conditions include Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1, Spinocerebellar Ataxia Genotype Type 2.

What happened to similar drugs?

0 of 7 similar drugs in Spinocerebellar Ataxias were approved

Approved (0) Terminated (0) Active (7)
🔄KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
🔄KPS-0373, High dose + KPS-0373, Low dose + PlaceboKissei PharmaceuticalPhase 3
🔄KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
🔄KPS-0373 + PlaceboKissei PharmaceuticalPhase 3
🔄KPS-0373 + PlaceboKissei PharmaceuticalPhase 3
🔄KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
🔄troriluzole + PlaceboBiohavenPhase 3

Hype Score Breakdown

Clinical
15
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02960893Phase 2/3Completed

Competing Products

15 competing products in Spinocerebellar Ataxias

See all competitors
ProductCompanyStageHype Score
KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
40
KPS-0373, High dose + KPS-0373, Low dose + PlaceboKissei PharmaceuticalPhase 3
40
KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
40
KPS-0373 + PlaceboKissei PharmaceuticalPhase 3
47
KPS-0373 + PlaceboKissei PharmaceuticalPhase 2
35
KPS-0373 + PlaceboKissei PharmaceuticalPhase 3
40
KPS-0373Kissei PharmaceuticalPhase 2
35
KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
40
varenicline + placeboPfizerPhase 2
35
BIIB132 + BIIB132-Matching PlaceboBiogenPhase 1
18
IVIGBaxterPhase 2
32
Intravenous Immune Globulin (IVIG)BaxterPhase 1
22
ARO-ATXN2 Injection + PlaceboArrowhead PharmaceuticalsPhase 1
33
BHV-4157BiohavenPre-clinical
24
troriluzole + PlaceboBiohavenPhase 3
38